Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study
<b>Background/Objectives</b>: Cannabidiol (CBD) is a non-intoxicating cannabinoid touted for a variety of medical benefits, including alleviation of anxiety. While legalization of hemp-derived products in the United States (containing ≤0.3% delta-9-tetrahydrocannabinol [d9-THC] by weight) has led to...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2025-08-01
|
| coleção: | Biomedicines |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/2227-9059/13/8/1874 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|